Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.56 |
| ▸ | FAP | Q12884 | 3/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874305 | 1.00 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3397659 | 1.00 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3793419 | 0.83 | DPP4 (0.57) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3784078 | 0.83 | DPP4 (0.57) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3783677 | 0.83 | DPP4 (0.57) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12861005 | 0.83 | DPP4 (0.55) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL16501402 | 0.83 | DPP4 (0.57) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3782633 | 0.83 | DPP4 (0.57) | DPP4FAPDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL27634730 | 0.81 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL25187601 | 0.81 | DPP4 (0.39) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893103-B2 | Dipeptidyl peptidase IV (DPP-IV); industrial scale process of making antidiabetics such as (2S,4S)-1-{2-[(3SR,1RS)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoro-pyrrolidine-2-carbonitrile starting from ethyl glyoxalate and 3-(1H-1,2,4-triazol-1-ylmethyl)cyclopententylamine for example | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-02-22 | — | — | US | disclosed |
| EP-2035395-A2 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2008001195-A2 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 103/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.